Share Price and Basic Stock Data
Last Updated: October 17, 2025, 11:05 pm
| PEG Ratio | 0.38 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Alkosign Ltd has shown a notable trajectory in its revenue generation over recent quarters. The company reported sales of ₹4.03 Cr in September 2021, which increased to ₹21.25 Cr by September 2023, marking a significant growth rate. The revenue for March 2024 stood at ₹35.69 Cr, reflecting a remarkable increase from ₹21.38 Cr in March 2023. This upward trend continued with a reported ₹51.53 Cr for March 2025. The expenses have also risen, from ₹3.38 Cr in September 2021 to ₹12.65 Cr in September 2023, and ₹43.72 Cr in March 2025, indicating the company’s scaling operations. The Operating Profit Margin (OPM) peaked at 40.47% in September 2023 but fell to 12.53% in March 2025, suggesting fluctuations in operational efficiency. This revenue growth, coupled with a diverse operational strategy, positions Alkosign Ltd favorably in its industry, despite the challenges of rising costs that have impacted profitability metrics.
Profitability and Efficiency Metrics
Profitability metrics for Alkosign Ltd indicate a mixed performance amid revenue growth. The net profit recorded in September 2023 was ₹5.80 Cr, a significant recovery from a net loss of ₹0.63 Cr in September 2022. However, the company faced challenges in March 2024, reporting a net loss of ₹5.02 Cr. The Earnings Per Share (EPS) reflected this volatility, with a high of ₹5.37 in September 2023, dropping to ₹0.43 in March 2025. The Interest Coverage Ratio (ICR) stood at a robust 7.47 times, indicating strong ability to meet interest obligations, while the Return on Equity (ROE) was reported at 12.0% and Return on Capital Employed (ROCE) at 12.8%, showcasing a reasonable return on investments. Nevertheless, the Cash Conversion Cycle (CCC) remained high at 240.36 days, reflecting potential inefficiencies in working capital management and the need for improved inventory turnover and receivables collection.
Balance Sheet Strength and Financial Ratios
Alkosign Ltd demonstrated a sound balance sheet as of March 2025, with total assets amounting to ₹51.05 Cr against total liabilities of ₹51.05 Cr, showcasing a balanced structure. The company’s equity capital stood at ₹7.20 Cr, while reserves increased significantly to ₹25.79 Cr, an increase from ₹6.71 Cr in March 2023, indicating strengthening shareholder equity. Borrowings decreased to ₹12.55 Cr, down from ₹20.40 Cr in March 2023, enhancing the company’s leverage position with a Debt to Equity ratio of 0.38. Liquidity ratios also appeared favorable, with a current ratio of 2.54 and a quick ratio of 1.24, suggesting good short-term financial health. The Price to Book Value (P/BV) ratio was reported at 2.09x, which, while indicating a premium valuation, suggests investor confidence in the company’s growth potential relative to its book value.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Alkosign Ltd reflects a diverse ownership structure. As of March 2025, promoters held 41.89% of the shares, a slight decline from 53.28% in March 2023, indicating a reduction in promoter control. Foreign Institutional Investors (FIIs) increased their stake to 9.94%, up from 0% in March 2022, signaling growing institutional interest. The public holds a significant 48.15%, which has remained stable over recent quarters, while the number of shareholders increased to 662, reflecting rising retail investor interest. This diverse shareholding structure may enhance market confidence, but the declining promoter stake could raise concerns about control and governance. The company’s ability to maintain investor trust will be crucial as it navigates challenges in profitability and operational efficiency.
Outlook, Risks, and Final Insight
If margins sustain at current levels, Alkosign Ltd could capitalize on its revenue growth trajectory. However, the company faces risks including potential fluctuations in operational costs and the high cash conversion cycle, which may strain liquidity. Additionally, the recent decline in promoter shareholding could affect governance and strategic direction. Should the company improve its efficiency metrics and manage its working capital effectively, it may enhance profitability and investor confidence. The increase in FII participation is a positive sign, indicative of external validation of the company’s growth story. Overall, while Alkosign Ltd is positioned for growth, it must address operational challenges to fully realize its potential in the competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Alkosign Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Metallic Coal & Coke Ltd | 5.94 Cr. | 30.0 | / | 77.6 | 0.00 % | 0.37 % | 2.00 % | 100 | |
| Gensol Engineering Ltd | 144 Cr. | 37.5 | 869/31.9 | 1.40 | 155 | 0.00 % | 14.3 % | 22.4 % | 10.0 |
| Fusion Micro Finance Ltd | 2,443 Cr. | 180 | 227/124 | 101 | 0.00 % | 2.96 % | 54.5 % | 10.0 | |
| Five X Tradecom Ltd | 0.99 Cr. | 0.48 | / | 9.35 | 0.00 % | 0.00 % | 0.00 % | 10.0 | |
| East West Holdings Ltd | 51.8 Cr. | 4.06 | 8.90/3.97 | 5.12 | 0.00 % | 6.98 % | 0.86 % | 2.00 | |
| Industry Average | 7,497.09 Cr | 260.67 | 362.86 | 100.64 | 0.22% | 11.73% | 22.92% | 9.18 |
Quarterly Result
| Metric | Sep 2021 | Mar 2022 | Sep 2022 | Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|
| Sales | 4.03 | 6.13 | 9.11 | 12.27 | 21.25 | 14.43 | 27.90 | 23.63 |
| Expenses | 3.38 | 5.91 | 8.18 | 10.38 | 12.65 | 18.52 | 23.06 | 20.67 |
| Operating Profit | 0.65 | 0.22 | 0.93 | 1.89 | 8.60 | -4.09 | 4.84 | 2.96 |
| OPM % | 16.13% | 3.59% | 10.21% | 15.40% | 40.47% | -28.34% | 17.35% | 12.53% |
| Other Income | -0.00 | 0.06 | 0.03 | 0.22 | 0.04 | 0.24 | 0.15 | 0.16 |
| Interest | 0.40 | 0.44 | 0.64 | 0.87 | 0.45 | 1.22 | 0.51 | 0.57 |
| Depreciation | 0.69 | 0.97 | 0.94 | 1.00 | 1.20 | 1.25 | 1.17 | 1.25 |
| Profit before tax | -0.44 | -1.13 | -0.62 | 0.24 | 6.99 | -6.32 | 3.31 | 1.30 |
| Tax % | -6.82% | -15.04% | 1.61% | 25.00% | 17.02% | -20.73% | -0.00% | 65.38% |
| Net Profit | -0.41 | -0.96 | -0.63 | 0.18 | 5.80 | -5.02 | 3.31 | 0.46 |
| EPS in Rs | -1.17 | -0.77 | 0.22 | 5.37 | -4.65 | 3.06 | 0.43 |
Last Updated: August 20, 2025, 12:05 am
Below is a detailed analysis of the quarterly data for Alkosign Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 23.63 Cr.. The value appears to be declining and may need further review. It has decreased from 27.90 Cr. (Sep 2024) to 23.63 Cr., marking a decrease of 4.27 Cr..
- For Expenses, as of Mar 2025, the value is 20.67 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 23.06 Cr. (Sep 2024) to 20.67 Cr., marking a decrease of 2.39 Cr..
- For Operating Profit, as of Mar 2025, the value is 2.96 Cr.. The value appears to be declining and may need further review. It has decreased from 4.84 Cr. (Sep 2024) to 2.96 Cr., marking a decrease of 1.88 Cr..
- For OPM %, as of Mar 2025, the value is 12.53%. The value appears to be declining and may need further review. It has decreased from 17.35% (Sep 2024) to 12.53%, marking a decrease of 4.82%.
- For Other Income, as of Mar 2025, the value is 0.16 Cr.. The value appears strong and on an upward trend. It has increased from 0.15 Cr. (Sep 2024) to 0.16 Cr., marking an increase of 0.01 Cr..
- For Interest, as of Mar 2025, the value is 0.57 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.51 Cr. (Sep 2024) to 0.57 Cr., marking an increase of 0.06 Cr..
- For Depreciation, as of Mar 2025, the value is 1.25 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.17 Cr. (Sep 2024) to 1.25 Cr., marking an increase of 0.08 Cr..
- For Profit before tax, as of Mar 2025, the value is 1.30 Cr.. The value appears to be declining and may need further review. It has decreased from 3.31 Cr. (Sep 2024) to 1.30 Cr., marking a decrease of 2.01 Cr..
- For Tax %, as of Mar 2025, the value is 65.38%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Sep 2024) to 65.38%, marking an increase of 65.38%.
- For Net Profit, as of Mar 2025, the value is 0.46 Cr.. The value appears to be declining and may need further review. It has decreased from 3.31 Cr. (Sep 2024) to 0.46 Cr., marking a decrease of 2.85 Cr..
- For EPS in Rs, as of Mar 2025, the value is 0.43. The value appears to be declining and may need further review. It has decreased from 3.06 (Sep 2024) to 0.43, marking a decrease of 2.63.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: July 22, 2025, 2:36 pm
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Sales | 13.24 | 13.24 | 10.16 | 21.38 | 35.69 | 51.53 |
| Expenses | 11.85 | 11.85 | 9.28 | 18.55 | 31.18 | 43.72 |
| Operating Profit | 1.39 | 1.39 | 0.88 | 2.83 | 4.51 | 7.81 |
| OPM % | 10.50% | 10.50% | 8.66% | 13.24% | 12.64% | 15.16% |
| Other Income | 0.03 | 0.03 | 0.05 | 0.25 | 0.28 | 0.32 |
| Interest | 0.31 | 0.31 | 0.84 | 1.51 | 1.67 | 1.09 |
| Depreciation | 0.20 | 0.20 | 1.66 | 1.95 | 2.45 | 2.42 |
| Profit before tax | 0.91 | 0.91 | -1.57 | -0.38 | 0.67 | 4.62 |
| Tax % | 27.47% | 27.47% | -12.74% | 21.05% | -16.42% | 18.40% |
| Net Profit | 0.66 | 0.66 | -1.38 | -0.46 | 0.78 | 3.77 |
| EPS in Rs | -1.68 | -0.56 | 0.72 | 3.49 | ||
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 9.23% | 0.00% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -309.09% | 66.67% | 269.57% | 383.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -309.09% | 375.76% | 202.90% | 113.77% |
Alkosign Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 72% |
| TTM: | 44% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 42% |
| 3 Years: | 68% |
| TTM: | 409% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 22% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | 6% |
| Last Year: | 12% |
Last Updated: September 5, 2025, 2:11 pm
Balance Sheet
Last Updated: October 10, 2025, 3:24 pm
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 0.01 | 5.45 | 5.45 | 7.20 | 7.20 |
| Reserves | 0.66 | 0.66 | 7.17 | 6.71 | 22.02 | 25.79 |
| Borrowings | 20.47 | 20.47 | 16.03 | 20.40 | 13.85 | 12.55 |
| Other Liabilities | 2.52 | 2.37 | 0.88 | 2.23 | 6.76 | 5.51 |
| Total Liabilities | 23.66 | 23.51 | 29.53 | 34.79 | 49.83 | 51.05 |
| Fixed Assets | 1.56 | 1.56 | 15.95 | 18.35 | 16.93 | 16.31 |
| CWIP | 14.28 | 14.28 | 0.00 | 0.00 | 0.61 | 0.54 |
| Investments | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.00 |
| Other Assets | 7.72 | 7.57 | 13.48 | 16.34 | 32.19 | 34.20 |
| Total Assets | 23.66 | 23.51 | 29.53 | 34.79 | 49.83 | 51.05 |
Below is a detailed analysis of the balance sheet data for Alkosign Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 7.20 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 7.20 Cr..
- For Reserves, as of Mar 2025, the value is 25.79 Cr.. The value appears strong and on an upward trend. It has increased from 22.02 Cr. (Mar 2024) to 25.79 Cr., marking an increase of 3.77 Cr..
- For Borrowings, as of Mar 2025, the value is 12.55 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 13.85 Cr. (Mar 2024) to 12.55 Cr., marking a decrease of 1.30 Cr..
- For Other Liabilities, as of Mar 2025, the value is 5.51 Cr.. The value appears to be improving (decreasing). It has decreased from 6.76 Cr. (Mar 2024) to 5.51 Cr., marking a decrease of 1.25 Cr..
- For Total Liabilities, as of Mar 2025, the value is 51.05 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 49.83 Cr. (Mar 2024) to 51.05 Cr., marking an increase of 1.22 Cr..
- For Fixed Assets, as of Mar 2025, the value is 16.31 Cr.. The value appears to be declining and may need further review. It has decreased from 16.93 Cr. (Mar 2024) to 16.31 Cr., marking a decrease of 0.62 Cr..
- For CWIP, as of Mar 2025, the value is 0.54 Cr.. The value appears to be declining and may need further review. It has decreased from 0.61 Cr. (Mar 2024) to 0.54 Cr., marking a decrease of 0.07 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 0.10 Cr..
- For Other Assets, as of Mar 2025, the value is 34.20 Cr.. The value appears strong and on an upward trend. It has increased from 32.19 Cr. (Mar 2024) to 34.20 Cr., marking an increase of 2.01 Cr..
- For Total Assets, as of Mar 2025, the value is 51.05 Cr.. The value appears strong and on an upward trend. It has increased from 49.83 Cr. (Mar 2024) to 51.05 Cr., marking an increase of 1.22 Cr..
Notably, the Reserves (25.79 Cr.) exceed the Borrowings (12.55 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | -19.08 | -19.08 | -15.15 | -17.57 | -9.34 | -4.74 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 137.56 | 137.56 | 83.71 | 47.12 | 57.58 | 84.57 |
| Inventory Days | 115.21 | 115.21 | 202.07 | 267.67 | 278.07 | 203.40 |
| Days Payable | 98.90 | 98.90 | 31.43 | 32.54 | 97.88 | 47.61 |
| Cash Conversion Cycle | 153.88 | 153.88 | 254.34 | 282.25 | 237.77 | 240.36 |
| Working Capital Days | -164.03 | -163.20 | -105.26 | -14.00 | 109.33 | 120.13 |
| ROCE % | 5.77% | -2.89% | 3.69% | 6.06% | 12.78% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 |
|---|---|---|
| FaceValue | 10.00 | 10.00 |
| Basic EPS (Rs.) | 5.24 | 1.22 |
| Diluted EPS (Rs.) | 5.24 | 1.22 |
| Cash EPS (Rs.) | 8.60 | 4.50 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 45.84 | 40.61 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 45.84 | 40.61 |
| Revenue From Operations / Share (Rs.) | 71.62 | 49.60 |
| PBDIT / Share (Rs.) | 11.29 | 6.66 |
| PBIT / Share (Rs.) | 7.93 | 3.25 |
| PBT / Share (Rs.) | 6.42 | 0.92 |
| Net Profit / Share (Rs.) | 5.24 | 1.09 |
| NP After MI And SOA / Share (Rs.) | 5.24 | 1.09 |
| PBDIT Margin (%) | 15.76 | 13.41 |
| PBIT Margin (%) | 11.07 | 6.54 |
| PBT Margin (%) | 8.96 | 1.86 |
| Net Profit Margin (%) | 7.31 | 2.19 |
| NP After MI And SOA Margin (%) | 7.31 | 2.19 |
| Return on Networth / Equity (%) | 11.42 | 2.68 |
| Return on Capital Employeed (%) | 15.05 | 6.57 |
| Return On Assets (%) | 7.38 | 1.57 |
| Long Term Debt / Equity (X) | 0.14 | 0.21 |
| Total Debt / Equity (X) | 0.38 | 0.47 |
| Current Ratio (X) | 2.54 | 2.21 |
| Quick Ratio (X) | 1.24 | 1.07 |
| Interest Coverage Ratio (X) | 7.47 | 2.87 |
| Interest Coverage Ratio (Post Tax) (X) | 4.46 | 1.47 |
| Enterprise Value (Cr.) | 78.34 | 130.32 |
| EV / Net Operating Revenue (X) | 1.52 | 3.65 |
| EV / EBITDA (X) | 9.64 | 27.21 |
| MarketCap / Net Operating Revenue (X) | 1.34 | 3.45 |
| Price / BV (X) | 2.09 | 4.21 |
| Price / Net Operating Revenue (X) | 1.34 | 3.45 |
| EarningsYield | 0.05 | 0.01 |
After reviewing the key financial ratios for Alkosign Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.22 (Mar 24) to 5.24, marking an increase of 4.02.
- For Diluted EPS (Rs.), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.22 (Mar 24) to 5.24, marking an increase of 4.02.
- For Cash EPS (Rs.), as of Mar 25, the value is 8.60. This value is within the healthy range. It has increased from 4.50 (Mar 24) to 8.60, marking an increase of 4.10.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 45.84. It has increased from 40.61 (Mar 24) to 45.84, marking an increase of 5.23.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 45.84. It has increased from 40.61 (Mar 24) to 45.84, marking an increase of 5.23.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 71.62. It has increased from 49.60 (Mar 24) to 71.62, marking an increase of 22.02.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 11.29. This value is within the healthy range. It has increased from 6.66 (Mar 24) to 11.29, marking an increase of 4.63.
- For PBIT / Share (Rs.), as of Mar 25, the value is 7.93. This value is within the healthy range. It has increased from 3.25 (Mar 24) to 7.93, marking an increase of 4.68.
- For PBT / Share (Rs.), as of Mar 25, the value is 6.42. This value is within the healthy range. It has increased from 0.92 (Mar 24) to 6.42, marking an increase of 5.50.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 5.24, marking an increase of 4.15.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 5.24. This value is within the healthy range. It has increased from 1.09 (Mar 24) to 5.24, marking an increase of 4.15.
- For PBDIT Margin (%), as of Mar 25, the value is 15.76. This value is within the healthy range. It has increased from 13.41 (Mar 24) to 15.76, marking an increase of 2.35.
- For PBIT Margin (%), as of Mar 25, the value is 11.07. This value is within the healthy range. It has increased from 6.54 (Mar 24) to 11.07, marking an increase of 4.53.
- For PBT Margin (%), as of Mar 25, the value is 8.96. This value is below the healthy minimum of 10. It has increased from 1.86 (Mar 24) to 8.96, marking an increase of 7.10.
- For Net Profit Margin (%), as of Mar 25, the value is 7.31. This value is within the healthy range. It has increased from 2.19 (Mar 24) to 7.31, marking an increase of 5.12.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 7.31. This value is below the healthy minimum of 8. It has increased from 2.19 (Mar 24) to 7.31, marking an increase of 5.12.
- For Return on Networth / Equity (%), as of Mar 25, the value is 11.42. This value is below the healthy minimum of 15. It has increased from 2.68 (Mar 24) to 11.42, marking an increase of 8.74.
- For Return on Capital Employeed (%), as of Mar 25, the value is 15.05. This value is within the healthy range. It has increased from 6.57 (Mar 24) to 15.05, marking an increase of 8.48.
- For Return On Assets (%), as of Mar 25, the value is 7.38. This value is within the healthy range. It has increased from 1.57 (Mar 24) to 7.38, marking an increase of 5.81.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.14. This value is below the healthy minimum of 0.2. It has decreased from 0.21 (Mar 24) to 0.14, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.38. This value is within the healthy range. It has decreased from 0.47 (Mar 24) to 0.38, marking a decrease of 0.09.
- For Current Ratio (X), as of Mar 25, the value is 2.54. This value is within the healthy range. It has increased from 2.21 (Mar 24) to 2.54, marking an increase of 0.33.
- For Quick Ratio (X), as of Mar 25, the value is 1.24. This value is within the healthy range. It has increased from 1.07 (Mar 24) to 1.24, marking an increase of 0.17.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.47. This value is within the healthy range. It has increased from 2.87 (Mar 24) to 7.47, marking an increase of 4.60.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.46. This value is within the healthy range. It has increased from 1.47 (Mar 24) to 4.46, marking an increase of 2.99.
- For Enterprise Value (Cr.), as of Mar 25, the value is 78.34. It has decreased from 130.32 (Mar 24) to 78.34, marking a decrease of 51.98.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.52. This value is within the healthy range. It has decreased from 3.65 (Mar 24) to 1.52, marking a decrease of 2.13.
- For EV / EBITDA (X), as of Mar 25, the value is 9.64. This value is within the healthy range. It has decreased from 27.21 (Mar 24) to 9.64, marking a decrease of 17.57.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 3.45 (Mar 24) to 1.34, marking a decrease of 2.11.
- For Price / BV (X), as of Mar 25, the value is 2.09. This value is within the healthy range. It has decreased from 4.21 (Mar 24) to 2.09, marking a decrease of 2.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.34. This value is within the healthy range. It has decreased from 3.45 (Mar 24) to 1.34, marking a decrease of 2.11.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Alkosign Ltd:
- Net Profit Margin: 7.31%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 15.05% (Industry Average ROCE: 11.01%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 11.42% (Industry Average ROE: 20.11%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.46
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.24
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 21.7 (Industry average Stock P/E: 207.35)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.38
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 7.31%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Printing/Publishing/Stationery | Plot No. 12-A, Kalyan Bhiwandi Industrial Area, Thane Maharashtra 421311 | investor@alkosign.com https://www.alkosign.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Samir Narendra Shah | Chairman & Managing Director |
| Mr. Shrenik Kamlesh Shah | Whole Time Director |
| Mr. Akshay Narendra Shah | Non Executive Director |
| Ms. Zeenal Shrenik Shah | Non Executive Director |
| Mr. Parshva Vinaykant Doshi | Ind. Non-Executive Director |
| Mr. Yogesh Ramgopal Gupta | Ind. Non-Executive Director |
| Ms. Seema Ashim Jhaveri | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Alkosign Ltd?
Alkosign Ltd's intrinsic value (as of 17 October 2025) is 65.02 which is 13.19% lower the current market price of 74.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 80.8 Cr. market cap, FY2025-2026 high/low of 96.7/46.0, reserves of ₹25.79 Cr, and liabilities of 51.05 Cr.
What is the Market Cap of Alkosign Ltd?
The Market Cap of Alkosign Ltd is 80.8 Cr..
What is the current Stock Price of Alkosign Ltd as on 17 October 2025?
The current stock price of Alkosign Ltd as on 17 October 2025 is 74.9.
What is the High / Low of Alkosign Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Alkosign Ltd stocks is 96.7/46.0.
What is the Stock P/E of Alkosign Ltd?
The Stock P/E of Alkosign Ltd is 21.7.
What is the Book Value of Alkosign Ltd?
The Book Value of Alkosign Ltd is 30.6.
What is the Dividend Yield of Alkosign Ltd?
The Dividend Yield of Alkosign Ltd is 0.00 %.
What is the ROCE of Alkosign Ltd?
The ROCE of Alkosign Ltd is 12.8 %.
What is the ROE of Alkosign Ltd?
The ROE of Alkosign Ltd is 12.0 %.
What is the Face Value of Alkosign Ltd?
The Face Value of Alkosign Ltd is 10.0.